November 8, 2016 (Shareholders Foundation) - An investigation on behalf of investors of Diplomat Pharmacy Inc (NYSE:DPLO) shares over potential securities laws violations by Diplomat Pharmacy and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Diplomat Pharmacy Inc (NYSE:DPLO) concerning whether a series of statements by Diplomat Pharmacy Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Diplomat Pharmacy Inc reported that its annual Total Revenue rose from over $1.51 billion in 2013 to over $3.36 billion in 2015 and that its Net loss of $26.12 million in 2013 turned into a Net Income of $25.78 million in 2015.

On November 2, 2016, Diplomat Pharmacy Inc reported third quarter 2016 results. Diplomat Pharmacy Inc also lowered full year 2016 guidance, with the CEO and Chairman commenting, We are disappointed with our third quarter results, which were significantly impacted by the softness in the hepatitis C business nationwide, as well as by DIR fees. The methodology and transparency around how PBMs are applying these DIR fees changed materially in 2016, and while we cannot reverse the impact they had on this quarter, we are working with our partners in the specialty pharmacy industry and with legislators to achieve an amicable solution to this problem. Shares of Diplomat Pharmacy Inc (NYSE:DPLO) declined to as low as $12.47 per share on November 4, 2016.